CoChat

Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review

Open access
Yang, Chenghao, Wardenaar, Klaas J., Bosker, Fokko J., Li, Jie, Schoevers, Robert A. · 2019 · Journal of Affective Disorders
Cited by 146

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND A substantial percentage of depressed patients do not respond satisfactorily to conventional antidepressant treatment. This treatment resistant depression (TRD) may be partly related to inflammatory processes in the central nervous system. Accordingly, peripheral inflammatory markers might serve to predict treatment response with novel but still experimental forms of antidepressant treatment. METHODS A literature search on treatment of TRD and inflammatory markers was performed using the PubMed/Medline database on November 8th 2018, and 95 articles were retrieved initially, which were subsequently screened and selected only when the inclusion and exclusion criteria were met. RESULTS Ten studies were recruited. In five studies higher baseline interleukin-6 (IL-6) or C-reactive protein (CRP)/high-sensitivity-CRP (hsCRP) in blood predicted better response to medication with anti-inflammatory characteristics, such as ketamine and infliximab. One study found that higher IL-6 predicted worse response to antidepressant treatment in patients with TRD. No evidence was found for the predictive value of other inflammatory markers (e.g., Tumor Necrosis Factor-α, Interferon-γ). LIMITATIONS The number of available studies was limited; included studies showed considerable methodological variation and used different definitions for TRD. CONCLUSION The inflammatory markers IL-6 and CRP/hsCRP could hold promise as markers for the prediction of treatment response in TRD. Clearly, this field of research is still far from mature but it could pave the way for novel and efficacious treatments for at least the inflammatory type of TRD with more well-designed studies and more convincing results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jad.2019.07.045

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. Allen, 2018, Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: comparison of multiple ketamine infusions and electroconvulsive therapy, J. Psychiatr. Res., 100, 24, 10.1016/j.jpsychires.2018.02.011 · DOI
  2. Allison, 2019, The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: a systematic review of randomized clinical trials, Physiol. Behav., 207, 104, 10.1016/j.physbeh.2019.05.006 · DOI
  3. Ballesteros, 2007, Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD), J. Affect. Disord., 102, 93, 10.1016/j.jad.2006.12.015 · DOI
  4. Bekhbat, 2018, Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression, Psychoneuroendocrinology, 98, 222, 10.1016/j.psyneuen.2018.09.004 · DOI · Paper page
  5. Ben Menachem-Zidon, 2008, Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis, Neuropsychopharmacology, 33, 2251, 10.1038/sj.npp.1301606 · DOI
  6. Berman, 1997, Treatment-refractory depression: definitions and characteristics, Depress. Anxiety, 5, 154, 10.1002/(SICI)1520-6394(1997)5:4<154::AID-DA2>3.0.CO;2-D · DOI · Paper page
  7. Cai, 2016, Age and sex differences in immune response following LPS treatment in mice, Brain Behav. Immun., 58, 327, 10.1016/j.bbi.2016.08.002 · DOI
  8. Chauvet-Gelinier, 2012, Bipolar disorders and somatic comorbidities: a focus on metabollic syndrome, diabetes and cardiovascular disease, L'Encephale, 4, S167
  9. Chen, 2018, Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study, Acta Psychiatr. Scand., 269, 207
  10. Clarke, 2017, Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes, Neuropharmacology, 112, 210, 10.1016/j.neuropharm.2016.04.021 · DOI
  11. Gibson, 2010, Mental illness and public health: exploring the role of general hospital physicians at a teaching hospital in Jamaica, West Indian Med. J., 59, 662
  12. Goshen, 2007, A dual role for interleukin-1 in hippocampal-dependent memory processes, Psychoneuroendocrinology, 32, 1106, 10.1016/j.psyneuen.2007.09.004 · DOI · Paper page
  13. Grieve, 2016, Prediction of nonremission to antidepressant therapy using diffusion tensor imaging, J. Clin. Psychiatry, 77, e436, 10.4088/JCP.14m09577 · DOI · Paper page
  14. Heimann, 1974, Therapy-resistant depressions: symptoms and syndromes. Contributions to symptomatology and syndromes., Pharmakopsychiatr. Neuropsychopharmakol., 7, 139, 10.1055/s-0028-1094412 · DOI · Paper page
  15. Kagawa, 2017, Both serum brain-derived neurotrophic factor and Interleukin-6 levels are not associated with therapeutic response to lamotrigine augmentation therapy in treatment-resistant depressive disorder, Neuropsychobiology, 75, 145, 10.1159/000484665 · DOI
  16. Kent, 1992, Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1, Proc. Natl. Acad. Sci. U.S.A., 89, 9117, 10.1073/pnas.89.19.9117 · DOI · Paper page
  17. Kiraly, 2017, Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome, Transl. Psychiatry, 7, e1065, 10.1038/tp.2017.31 · DOI · Paper page
  18. Klein, 2015, Sex-based differences in immune function and responses to vaccination, Trans. R. Soc. Trop. Med. Hyg., 109, 9, 10.1093/trstmh/tru167 · DOI · Paper page
  19. Klisic, 2018, Relationship between oxidative stress, inflammation and dyslipidemia with fatty liver index in patients with type 2 diabetes mellitus, Exp. Clin. Endocrinol. Diabetes, 126, 371, 10.1055/s-0043-118667 · DOI
  20. Kranaster, 2018, Antidepressant efficacy of electroconvulsive therapy is associated with a reduction of the innate cellular immune activity in the cerebrospinal fluid in patients with depression, World J. Biol. Psychiatry, 19, 379, 10.1080/15622975.2017.1355473 · DOI
  21. Kronfol, 1985, Multiple sclerosis and depression, Arch. Neurol., 42, 310, 10.1001/archneur.1985.04060040016004 · doi:10.1001/archneur.1985.04060040016004
  22. Kronfol, 1985, Depression, cortisol metabolism and lymphocytopenia, J. Affect. Disord., 9, 169, 10.1016/0165-0327(85)90097-7 · DOI
  23. Kruse, 2018, Inflammation and improvement of depression following electroconvulsive therapy in treatment-resistant depression, J. Clin. Psychiatry, 79, 10.4088/JCP.17m11597 · DOI · Paper page
  24. Lehmann, 1974, Therapy-resistant depressions - a clinical classification, Pharmakopsychiatr. Neuropsychopharmakol., 7, 156, 10.1055/s-0028-1094425 · DOI
  25. Li, 2017, Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1beta, and TNF-alpha in the hippocampus of mice following acute or chronic administration, Front. Pharmacol., 8, 139
  26. Mao, 2018, Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression, J. Affect. Disord., 237, 65, 10.1016/j.jad.2018.04.115 · DOI · Paper page
  27. Marnell, 2005, C-reactive protein: ligands, receptors and role in inflammation, Clin. Immunol., 117, 104, 10.1016/j.clim.2005.08.004 · DOI · Paper page
  28. McIntyre, 2005, Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale, CMAJ, 173, 1327, 10.1503/cmaj.050786 · DOI · Paper page
  29. Nemeroff, 2007, The burden of severe depression: a review of diagnostic challenges and treatment alternatives, J. Psychiatr. Res., 41, 189, 10.1016/j.jpsychires.2006.05.008 · DOI · Paper page
  30. Papakostas, 2014, Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial, J. Clin. Psychiatry, 75, 855, 10.4088/JCP.13m08947 · DOI · Paper page
  31. Paudel, 2017, "2-(4-Fluorobenzamido)-4-methylthiazole-5-carboxylic acid" a novel thiazole compound, ameliorates insulin sensitivity and hyperlipidaemia in streptozotocin-induced diabetic rats: plausible role of inflammatory and oxidative stress markers, Biomed. Pharmacother., 95, 1232, 10.1016/j.biopha.2017.09.014 · DOI
  32. Plata-Salaman, 1993, Centrally administered bacterial lipopolysaccharide depresses feeding in rats, Pharmacol. Biochem. Behav., 46, 787, 10.1016/0091-3057(93)90202-5 · DOI
  33. Prado, 2018, Anti-Inflammatory effects of melatonin in obesity and hypertension, Curr. Hypertens. Rep., 20, 45, 10.1007/s11906-018-0842-6 · DOI
  34. Sas, 2007, Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders, J. Neurol. Sci., 257, 221, 10.1016/j.jns.2007.01.033 · DOI · Paper page
  35. Scott, 2003, Global burden of depression: the intersection of culture and medicine, Br. J. Psychiatry, 183, 92, 10.1192/bjp.183.2.92 · DOI · Paper page
  36. Soczynska, 2009, The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?, Neurotoxicology, 30, 497, 10.1016/j.neuro.2009.03.004 · DOI
  37. Vinberg, 2016, Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: a randomised controlled study, Brain Behav. Immun., 57, 53, 10.1016/j.bbi.2016.05.006 · DOI
  38. Wu, 2007, Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory, J. Neurochem., 103, 2471, 10.1111/j.1471-4159.2007.04987.x · DOI · Paper page
  39. Yang, 2018, Interleukin, tumor necrosis factor-alpha and C-reactive protein profiles in melancholic and non-melancholic depression: a systematic review, J. Psychosom. Res., 111, 58, 10.1016/j.jpsychores.2018.05.008 · DOI · Paper page
  40. Yang, 2015, Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression, Biol. Psychiatry, 77, e19, 10.1016/j.biopsych.2014.06.021 · DOI · Paper page
  41. Yoshimura, 2009, Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, 33, 722, 10.1016/j.pnpbp.2009.03.020 · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Yang, C., Wardenaar, K. J., Bosker, F. J., Li, J., & Schoevers, R. A.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2019-10
Volume
257
Pages
640-649
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2954955957
Cited by
146
References
22
FWCI
3.68
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Tianjin Municipal Health Bureau (13KG118)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.